RecruitingNot ApplicableNCT05205980
Perturbation Training Reduces Falls in People With Alzheimer's Disease (AD)
Motor Learning of Fall Resistant Skills From Laboratory-induced Falling Among People With Mild Alzheimer's Disease
Sponsor
Georgia State University
Enrollment
30 participants
Start Date
Apr 28, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
This study will examine the overall capacity of people with Alzheimer's disease learning fall-resistant skills from perturbation training.
Eligibility
Min Age: 65 YearsMax Age: 90 Years
Inclusion Criteria6
- Participants must be at least 65 years old;
- Participants have a clinical diagnosis of probable AD;
- Participants can read and understand English;
- Participants must be able to walk independently at least 25 feet;
- Participants must be able to stand independently for at least 30 seconds;
- Participants must have a Montreal Cognitive Assessment score of 11-21 or Mini Mental Status Examination score between 18 and 23.
Exclusion Criteria4
- Individuals have ever experienced perturbation training;
- Individuals have hypotension or uncontrolled hypertension;
- Individuals exhibit osteoporosis;
- Participants suffer from coexisting psychiatric disorders, or other neurological conditions, or injuries, etc.
Interventions
BEHAVIORALPerturbation training
Participants will experience repeated perturbations mixed with non-perturbed trials on the treadmill with the protection by a harness.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05205980
Related Trials
Novel Augmentation of DAOIB and Antioxidant for Early Dementia
NCT064675391 location
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229241 locations
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
NCT041233141 location
Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease
NCT071782101 location
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
NCT07011732157 locations